期刊
NEUROPSYCHOPHARMACOLOGY
卷 31, 期 3, 页码 651-658出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.npp.1300886
关键词
orbitofrontal cortex; methylphenidate; risk-taking; decision-making; frontal variant frontotemporal dementia
资金
- Medical Research Council [G108/653, G0001354, MC_U105559861] Funding Source: Medline
- Wellcome Trust [019407] Funding Source: Medline
- MRC [MC_U105559861, G108/653] Funding Source: UKRI
- Medical Research Council [G0001354, G0001354B, MC_U105559861, G108/653] Funding Source: researchfish
The frontal variant of frontotemporal dementia is a significant neurological condition worldwide. There exist few treatments available for the cognitive and behavioural sequelae of fvFTD. Previous research has shown that these patients display risky decision-making, and numerous studies have now demonstrated pathology affecting the orbitofrontal cortex. The present study uses a within-subjects, double-blind, placebo-controlled procedure to investigate the effects of a single dose of methylphenidate (40 mg) upon a range of different cognitive processes including those assessing prefrontal cortex integrity. Methylphenidate was effective in 'normalizing' the decision-making behavior of patients, such that they became less risk taking on medication, although there were no significant effects on other aspects of cognitive function, including working memory, attentional set shifting, and reversal learning. Moreover, there was an absence of the normal subjective and autonomic responses to methylphenidate seen in elderly subjects. The results are discussed in terms of the 'somatic marker' hypothesis of impaired decision-making following orbitofrontal dysfunction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据